Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai Opens Fourth Knowledge Center In India As Launch Pad For Next-generation Global Products; Focus On Affordability

This article was originally published in PharmAsia News

Executive Summary

Sitting on a 50-acre campus at Southern India's Jawaharlal Nehru Pharma City, Eisai's newly minted Knowledge Center India is the company's first integrated facility that includes API production and research functions in one site, bringing the company one step further toward creating a global supply and research hub

You may also be interested in...



Are Stars Finally Aligning For Takeda In India?

For the past four years, Takeda’s plans for a full-scale entry into India have remained just that – plans on paper. But will it be a laggard for much longer in this fast-changing key emerging market? There are signs that the time may now be ripe for Japan’s top pharma firm to take a more decisive plunge.

Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness

Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.

Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness

Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel